Clin2
NCT06104241Possibly a fitRecruiting

Cell therapy for advanced digestive cancers

Gastrointestinal Cancer

Part of Cancer, Digestive system clinical trials.

This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
14 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are 18 to 70 years old and willing to sign a consent form.
  • You have esophageal, stomach, pancreatic, or colorectal cancer that has come back or spread, and has not responded to at least two standard treatments.
  • A tumor tissue test shows a specific protein target (target protein positive).
  • Your blood counts, liver, and kidney function are within certain ranges (your doctor will confirm).
  • You are not pregnant, have no active infections, and are not on long-term steroids or blood thinners.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06104215Recruiting· Early Phase 1
BGT007H cells for advanced digestive cancer

This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.

Xuzhou, Jiangsu
NCT06152757Recruiting· Early Phase 1
Cell therapy for advanced gastrointestinal cancers

This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.

Zhengzhou, Henan
NCT06645301Not yet recruiting· Early Phase 1
BGT007 cell therapy for advanced pancreatic or colorectal cancer

This trial tests an experimental cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to standard treatments. The therapy uses your own immune cells, which are collected, modified, and given back to you to fight the cancer.

NCT06478225Recruiting
Cell therapy for advanced pancreatic cancer

This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.

Shanghai, Shanghai Municipality
NCT07735065Not yet recruiting· Phase 1
Personalized T-cell therapy for advanced gastrointestinal cancer

This trial tests a new type of cell therapy using your own immune cells (T-cells) that are specially trained to attack your cancer. It is for people with advanced gastrointestinal cancers like esophageal, stomach, or colon cancer that have not responded to other treatments.

NCT03614650Not yet recruiting· Phase 1/Phase 2
Immunotherapy for advanced digestive system cancer

This trial tests an immunotherapy that uses your own immune cells to fight advanced digestive-system cancers. It aims to see if this treatment is safe and if it can help shrink tumors or slow their growth.

Shenzhen, Guangdong

Hear when a new Gastrointestinal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.